Literature DB >> 7237803

Charcoal hemoperfusion for treatment of carbamazepine poisoning.

K M Chan, J J Aguanno, R Jansen, D N Dietzler.   

Abstract

We report a case of carbamazepine (Tegretol) poisoning that was treated with charcoal hemoperfusion. When admitted, the patient was comatose and required ventilatory support. Hemoperfusion with coated activated charcoal successfully decreased her serum carbamazepine concentration from 60 mg/L to 36 mg/L within 2 h, with subsequent clinical improvement. Approximately 39 h would have been required to obtain this decrease via the patient's inherent elimination rate. Activated charcoal hemoperfusion may be useful as an adjunctive therapy for patients in advanced comatose states with associated respiratory depression and potentially fatal outcome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237803

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Cardiac complications of carbamazepine intoxication: treatment by haemoperfusion.

Authors:  P J Leslie; R Heyworth; L F Prescott
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-26

2.  Signs and symptoms of carbamazepine overdose.

Authors:  S Schmidt; M Schmitz-Buhl
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

Review 3.  Carbamazepine overdose. Features of 33 cases.

Authors:  J F Seymour
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 4.  Carbamazepine toxicity and poisoning. Incidence, clinical features and management.

Authors:  L Durelli; U Massazza; R Cavallo
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 5.  Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Marc Ghannoum; Christopher Yates; Tais F Galvao; Kevin M Sowinski; Thi Hai Vân Vo; Andrew Coogan; Sophie Gosselin; Valery Lavergne; Thomas D Nolin; Robert S Hoffman
Journal:  Clin Toxicol (Phila)       Date:  2014-10-30       Impact factor: 4.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.